2016 American Transplant Congress
Calcineurin Inhibitor (CNI) Nephrotoxicity Is Mediated by Defective Amp-Activated Protein Kinase (AMPK) Activation.
Medicine, UAB, Birmingham, AL.
Background: CNIs are potent immunosuppressant therapies, but associated with nephrotoxicity manifested by interstitial fibrosis and progressive graft dysfunction. AMPK is a major sensor and regulator…2016 American Transplant Congress
Novel Nuclear Factor-κB Activation Inhibitor, Dehydroxymethylepoxyquinomicin, Prevents the Development of Chronic Cyclosporine Nephropathy in Rats.
Purpose:The nephrotoxicity of the calcineurin inhibitors including cyclosporine is a major problem in the kidney transplantation. We investigated the effect of a novel nuclear factor-κB…2016 American Transplant Congress
Genomic-Derived Markers to Identify Calcineurin Inhibitor Nephrotoxicity in Pediatric Kidney Transplant Recipients.
Background:Calcineurin inhibitor nephrotoxicity (CNIT) is a well-known contributor to chronic allograft dysfunction in kidney transplant recipients (KTRs). Pediatric KTRs are particularly at risk given their…2016 American Transplant Congress
Adding an Antimetabolite to a Calcineurin-Inhibitor-Based Immunosuppression Regimen Leads to Improved Native Renal Function After Liver Transplantation.
Surgery, University of Wisconsin, Madison, WI.
Background: Nephrotoxic side effects of calcineurin inhibitors (CNI) have been well established. The addition of anti-metabolites (AM) to CNI-based immunosuppression (IS) regimens has been proposed…2016 American Transplant Congress
Tacrolimus Precision Medicine: Antibiotics Increase Intra-Patient Variability in Tacrolimus Trough Concentrations in Kidney Transplant Recipients.
Medicine/Nephrology and Hyeprtension, Weill Cornell Medical College, New York, NY.
BACKGROUND. The gut microbiome impacts drug absorption, metabolism, and distribution and was recently shown to be associated with tacrolimus dosing requirements. Since antibiotics can alter…2016 American Transplant Congress
Virological Response at 4 Weeks With a Sofosbuvir-Based Antiviral Regimen in Liver Transplant Recipients with Recurrent Hepatitis C.
Background: The literature is growing in the area of safety, efficacy and tolerability of sofosbuvir (SOF)- based antivirals therapy (AVT) in recurrent hepatitis C virus…2016 American Transplant Congress
Early Proteomic Predictors of Late Chronic Kidney Disease in Liver Transplant Recipients.
1Northwestern, Chicago; 2Baylor, Dallas.
Background: A high proportion of patients develop chronic kidney disease (CKD) after liver transplantation (LT). However, the ability to better select patients for nephroprotective interventions…2016 American Transplant Congress
Conversion from Tacrolimus to Belatacept in Pancreas Transplant Alone Recipients with Chronic Kidney Disease.
Medicine/Nephrology & Surgery/Transplant, Indiana University, Indianapolis.
Background: CNI toxicity is a well known risk factor for chronic kidney disease and ESRD in organ transplants. We report our experience in converting Pancreas…2016 American Transplant Congress
Calcineurin Inhibitors Promote Metastasis in Post-Transplant Colorectal Cancer Through Cancer Related- Exosomes Released from Cancer Cells in TGF Beta Independent Epitheilal to Mesenquimal Transition.
Introduction: Cancer is one of the major causes of death in kidney transplantation. Despite more mortality in colon cancer (CRC), similar incidence than general population…2016 American Transplant Congress
Early Conversion to Everolimus in De Novo Renal Transplant Recipients: Incidence of Viral Infections in the Randomized-Controlled ELEVATE Study.
BackgroundCytomegalovirus (CMV) and BK polyomavirus (BKPyV) infections are independent risk factors for acute rejection and graft loss. Early conversion from calcineurin inhibitors (CNIs) to everolimus…
- « Previous Page
- 1
- …
- 11
- 12
- 13
- 14
- 15
- 16
- Next Page »